BERAPROST EFFICACY AND SAFETY IN PULMONARY ARTERIAL HYPERTENSION: A RANDOMIZED, CONTROLLED TRIAL
Main Article Content
Keywords
Pulmonary arterial hypertension, beraprost, prostacyclin receptor agonist, randomised controlled trial.
Abstract
Pulmonary arterial hypertension (PAH) is a gross illness with a poor prognosis and limited management plans; pulmonary arterial hypertension usually centers on endothelin, nitric oxide, and prostacyclin paths. In a bid to test the efficacy and safety of beraprost, an oral selective prostacyclin receptor agonist, an event-driven phase 3, blinded experiment was conducted, and 801 patients with PAH were enrolled to test the efficacy and safety effects of the drug against the placebo in a blind. The purpose of the research was to examine the possibility to minimize the risks of mortality or complications regarding PAH with the utilization of beraprost. Compared with placebo, beraprost also showed a significant result on the primary composite endpoint that is the reduction of death or PAH-related complications (HR 0.60; 99% CI: 0.46-0.78). Even though the mortality of all-causes showed no statistically significant difference between the groups, the course of the disease and the hospitalizations were statistically significantly reduced in the beraprost group. The most common side effects observed were headache, diarrhea and nausea with majority being mild to moderate in nature and favored the beraprost group. The reported results indicate an impressive clinical usefulness of beraprost to account for decreased complications related to PAH, with the necessary improvements in dosing regimens and future outcomes.
References
2. Galiè, N.; Humbert, M.; Vachiery, J-L.; et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015, 46, 903-975.
3. Galiè, N.; Corris, P.A.; Frost, A.; et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013, 62, Suppl, D60-D72.
4. Barst, R.J.; Rubin, L.J.; Long, W.A.; et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996, 334, 296-301.
5. Farber, H.W.; Miller, D.P.; Meltzer, L.A.; McGoon, M.D. Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry. J Heart Lung Transplant 2013, 32, 1114-1122.
6. Benza, R.L.; Miller, D.P.; Barst, R.J.; Badesch, D.B.; Frost, A.E.; McGoon, M.D. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 2012, 142, 448-456.
7. McLaughlin, V.V.; Langer, A.; Tan, M.; et al. Contemporary trends in the diagnosis and management of pulmonary arterial hypertension: an initiative to close the care gap. Chest 2013, 143, 324-332.
8. Morrison, K.; Ernst, R.; Hess, P.; Studer, R.; Clozel, M. Beraprost: a selective prostacyclin receptor agonist that does not affect rat gastric function. J Pharmacol Exp Ther 2010, 335, 249-255.
9. Morrison, K.; Studer, R.; Ernst, R.; Haag, F.; Kauser, K.; Clozel, M. Differential effects of beraprost and prostacyclin analogs in rat pulmonary artery. J Pharmacol Exp Ther 2012, 343, 547-555.
10. Kuwano, K.; Hashino, A.; Asaki, T.; et al. 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther 2007, 322, 1181-1188.
11. Kuwano, K.; Hashino, A.; Noda, K.; Kosugi, K.; Kuwabara, K. A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, 4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxyacetic acid (MRE-269), on rat pulmonary artery. J Pharmacol Exp Ther 2008, 326, 691-699.
12. Simonneau, G.; Torbicki, A.; Hoeper, M.M.; et al. Beraprost: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J 2012, 40, 874-880.
13. Cuzick, J. Forest plots and the interpretation of subgroups. Lancet 2005, 365, 1308-1308.
14. Schulman, S.; Kearon, C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005, 3, 692-694.
15. Rajkumar, R.; Konishi, K.; Richards, T.J.; et al. Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension. Am J Physiol Heart Circ Physiol 2010, 298, H1235-H1248.
16. Tapson, V.F.; Torres, F.; Kermeen, F.; et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest 2012, 142, 1383-1390.
17. Tapson, V.F.; Jing, Z.C.; Xu, K.F.; et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest 2013, 144, 952-958.
18. McLaughlin, V.V.; Benza, R.L.; Rubin, L.J.; et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010, 55, 1915-1922.
19. Pulido, T.; Adzerikho, I.; Channick, R.N.; et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013, 369, 809-818.
20. Ghofrani, H.A.; Galiè, N.; Grimminger, F.; et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013, 369, 330-340.
21. Galiè, N.; Brundage, B.H.; Ghofrani, H.A.; et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009, 119, 2894-2903.
22. McLaughlin, V.V.; Oudiz, R.J.; Frost, A.; et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006, 174, 1257-1263.
23. McLaughlin, V.V.; Palevsky, H.I. Parenteral and inhaled prostanoid therapy in the treatment of pulmonary arterial hypertension. Clin Chest Med 2013, 34, 825-840.
24. McLaughlin, V.V.; Badesch, D.B.; Delcroix, M.; et al. End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol 2009, 54, Suppl, S97-S107.
25. McMurray, J.J.; Packer, M.; Desai, A.S.; et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014, 371, 993-1004.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr. Pradeep Kiran Pachandi
Assistant Professor, Sri Lakshmi Narayana Institute of Medical Science, Puducherry 605502, India
Dr.Anisha G
Assistant Professor, Sri Lakshmi Narayana Institute of Medical Science, Puducherry 605502, India